Insulet Corpor…
ProfileJobs

Insulet Corporation

Suggest Edit
    • HealthTechnologydiabeteshealthtechmedical devices

    Insulet Corporation, a medical device company, develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The Company offers Omnipod Insulin Management System (Omnipod System), which consists of the OmniPod, an easy-to-use continuous insulin delivery system and Personal Diabetes Manager, a handheld wireless device. It also customizes the Omnipod System technology platform for the delivery of subcutaneous drugs across various therapeutic areas. Insulet Corporation sells and markets its Omnipod System through a combination of direct sales representatives and independent distributors.

    Revenue(FY, 2016)
    $367 M
    Market capitalization(2018-06-14)
    $5.8 B
    Type
    Public
    HQ
    Billerica, US
    Founded
    2000
    Size (employees)
    640 (est)
    Website
    insulet.com
    Insulet Corporation was founded in 2000 and is headquartered in Billerica, US
    Report incorrect company information

    Key People/Management at Insulet Corporation

    Patrick Sullivan

    Patrick Sullivan

    Chairman of the Board and Chief Executive Officer
    Aiman Abdel-Malek

    Aiman Abdel-Malek

    Senior Vice President, Advanced Technology and Engineering
    Bret Christensen

    Bret Christensen

    Senior Vice President and Chief Commercial Officer
    David Colleran

    David Colleran

    Senior Vice President, Secretary and General Counsel
    Deborah Gordon

    Deborah Gordon

    Vice President, Investor Relations and Corporate Communications
    Michael Levitz

    Michael Levitz

    Senior Vice President, Chief Financial Officer and Treasurer
    Show more

    Insulet Corporation Office Locations

    Insulet Corporation has offices in Billerica, Denver, Tulsa, Washington and in 11 other locations
    Billerica, US (HQ)
    200 600 Technology Park Dr
    Show all (15)
    Report incorrect company information

    Insulet Corporation Financials and Metrics

    Insulet Corporation Financials

    Insulet Corporation's revenue was reported to be $366.99 m in FY, 2016 which is a 13.2% increase from the previous period.
    USD

    Revenue (Q1, 2018)

    		123.6 m

    Gross profit (Q1, 2018)

    		75.8 m

    Gross profit margin (Q1, 2018), %

    		61.3%

    Net income (Q1, 2018)

    		(6.6 m)

    Market capitalization (14-Jun-2018)

    		5.8 b

    Closing share price (14-Jun-2018)

    		99.1

    Cash (31-Mar-2018)

    		203.1 m
    Insulet Corporation's current market capitalization is $5.8 b.
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016

    Revenue

    		247.1 m288.7 m324.2 m367 m

    Revenue growth, %

    		17%12%13%

    Cost of goods sold

    		134.7 m145.4 m176.1 m155.9 m

    Gross profit

    		112.4 m143.3 m148.2 m211.1 m
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

    Revenue

    		61.1 m69.2 m72 m75 m61.2 m75.6 m87.3 m81.2 m87.3 m94.9 m101.7 m109.8 m123.6 m

    Cost of goods sold

    		33.7 m36.4 m36.2 m36.9 m28.4 m41.2 m51.7 m37.2 m36.9 m39.2 m42.3 m45.1 m47.8 m

    Gross profit

    		27.4 m32.8 m35.8 m38 m32.8 m34.4 m35.7 m44.1 m50.5 m55.6 m59.4 m64.6 m75.8 m

    Gross profit Margin, %

    		45%47%50%51%54%45%41%54%58%59%58%59%61%
    show all
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016

    Cash

    		149.7 m151.2 m122.7 m137.2 m

    Accounts Receivable

    		33.1 m39.9 m48.4 m28.8 m

    Inventories

    		9.5 m13.1 m5.7 m35.5 m

    Current Assets

    		198.2 m208.2 m190.8 m370 m
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

    Cash

    		153.9 m145.6 m175.5 m146.4 m145.6 m145.1 m145.5 m111.6 m75.7 m215.4 m76 m73.5 m203.1 m

    Accounts Receivable

    		34.5 m36.7 m41.8 m47.1 m36.1 m31.8 m31.8 m40.5 m38.7 m38.5 m40.6 m37.8 m50.4 m

    Inventories

    		5.4 m10.4 m8.8 m9.7 m20.1 m23.4 m13 m14 m24.5 m32.7 m34.3 m34 m26.3 m

    Current Assets

    		199.7 m199.9 m231.8 m206.6 m205.4 m203.8 m194.3 m171.8 m181.3 m361.8 m337.2 m338.7 m451.6 m
    show all
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016

    Net Income

    		(45 m)(51.5 m)(73.5 m)(28.9 m)

    Depreciation and Amortization

    		11.8 m12.2 m15.8 m13.8 m

    Inventories

    		5.4 m(3.6 m)(722 k)(24.1 m)

    Cash From Operating Activities

    		3.3 m8.9 m(12.6 m)15.9 m
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

    Net Income

    		(42.5 m)(6.1 m)(35.3 m)(46.1 m)(11.8 m)(27.3 m)(46.2 m)(12.5 m)(16.7 m)(19.8 m)(10 m)(17.7 m)(6.6 m)

    Depreciation and Amortization

    		8.9 m3.1 m6.1 m9.2 m3.4 m7.1 m11.4 m3.4 m6.8 m10.5 m3.3 m6.7 m3.5 m

    Inventories

    		9.5 m(985 k)699 k(198 k)(7 m)(10.3 m)312 k(2.6 m)(13.1 m)(21.3 m)1.2 m1.5 m6.7 m

    Cash From Operating Activities

    		6.9 m(1 m)(509 k)4.3 m(3.5 m)(2.7 m)(10.5 m)(6.8 m)(4.2 m)(21.8 m)(3.9 m)(4.3 m)
    show all
    USDY, 2018

    Financial Leverage

    		4.9 x
    Show all financial metrics

    Insulet Corporation Operating Metrics

    FY, 2016

    Patents Issued

    		23

    Patents Pending

    		32
    Show all operating metrics

    Insulet Corporation Revenue Breakdown

    Embed Graph

    Insulet Corporation revenue breakdown by business segment: 62.6% from U.S. Omnipod, 19.6% from International Omnipod and 17.8% from Drug Delivery

    Report incorrect company information

    Competitors

    mySugr
    Health - Subsidiary
    DreaMed Diabetes
    Health - Private
    Antares Pharma
    Health - Public
    Freedom Meditech
    Health - Private
    Compare competitors

    Insulet Corporation Online and Social Media Presence

    Embed Graph
    Report incorrect company information
    Download PDF